ATHE · Alterity Therapeutics Limited

This 6-K serves solely as a procedural filing to incorporate Exhibit 99.1, titled 'Consolidation/Split - ATH'. The exhibit itself is referenced only by name and image label — no descriptive text, effective date, ratio, share count impact, or regulatory rationale is provided in the document. As a development-stage biotechnology company with no commercial products, Alterity Therapeutics has not disclosed any earnings, R&D progress, clinical updates, financing activity, or governance changes in this submission. The absence of substantive content beyond the exhibit reference means investors receive no new operational, financial, or strategic information. The filing’s sole function appears to be administrative compliance, likely fulfilling an internal or jurisdictional requirement related to the ATH consolidation or split. Without further detail in Exhibit 99.1 — which is not included in the provided text — the market impact is negligible.